Azitra, Inc. Announces Reverse Stock Split
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced a 1-for-6.66 reverse stock split effective August 21, 2025. The company's common stock will continue trading under the symbol "AZTR" on the NYSE American with a new CUSIP number 05479L302.
The reverse split will reduce Azitra's outstanding shares from 23,476,354 to approximately 3,524,978. Stockholders will receive cash in lieu of fractional shares, calculated based on the average closing prices for the five trading days before the split. The split will proportionally adjust equity awards and warrants, including their exercise prices.
["Will help maintain NYSE American listing requirements", "No change to stockholder's percentage ownership in the company", "Stockholders automatically receive cash for fractional shares"]Azitra (NYSE American: AZTR), societ脿 biofarmaceutica in fase clinica specializzata in dermatologia di precisione, ha annunciato un raggruppamento azionario inverso 1 per 6,66 con efficacia il 21 agosto 2025. Le azioni ordinarie della societ脿 continueranno a negoziare con il simbolo "AZTR" sulla NYSE American con un nuovo numero CUSIP 05479L302.
Il raggruppamento ridurr脿 il numero di azioni in circolazione di Azitra da 23,476,354 a circa 3,524,978. Gli azionisti riceveranno denaro in luogo di azioni frazionarie, calcolato in base al prezzo medio di chiusura dei cinque giorni di negoziazione precedenti al raggruppamento. L'operazione adeguer脿 proporzionalmente i premi azionari e i warrant, inclusi i relativi prezzi d'esercizio.
- Aiuter脿 a mantenere i requisiti di quotazione della NYSE American
- Non cambia la percentuale di partecipazione degli azionisti nella societ脿
- Gli azionisti riceveranno automaticamente denaro per le azioni frazionarie
Azitra (NYSE American: AZTR), una compa帽铆a biofarmac茅utica en fase cl铆nica especializada en dermatolog铆a de precisi贸n, ha anunciado una consolidaci贸n inversa de acciones 1 por 6,66 con vigencia el 21 de agosto de 2025. Las acciones ordinarias de la compa帽铆a seguir谩n cotizando bajo el s铆mbolo "AZTR" en la NYSE American con un nuevo n煤mero CUSIP 05479L302.
La consolidaci贸n reducir谩 las acciones en circulaci贸n de Azitra de 23,476,354 a aproximadamente 3,524,978. Los accionistas recibir谩n efectivo en lugar de acciones fraccionarias, calculado en base a los precios de cierre promedio de los cinco d铆as h谩biles anteriores a la consolidaci贸n. La operaci贸n ajustar谩 proporcionalmente las concesiones de capital y los warrants, incluidos sus precios de ejercicio.
- Ayudar谩 a mantener los requisitos de cotizaci贸n de la NYSE American
- No cambia el porcentaje de participaci贸n de los accionistas en la compa帽铆a
- Los accionistas recibir谩n autom谩ticamente efectivo por las acciones fraccionarias
Azitra (NYSE American: AZTR)電� 鞝曤皜 頂茧秬瓿柬暀鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎巾殞靷, 1雽�6.66 鞐硲頃�鞚� 2025雲� 8鞗� 21鞚茧秬搿� 鞁滍枆頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 氤错喌欤茧姅 NYSE American鞐愳劀 鞁臣 "AZTR"搿� 瓿勳啀 瓯半灅霅橂┌ 靸堧鞖� CUSIP 氩堩樃電� 05479L302鞛呺媹雼�.
鞚措矆 鞐硲頃╈溂搿� Azitra鞚� 鞙犿喌 欤检嫕 靾橂姅 23,476,354欤检棎靹� 鞎� 3,524,978欤�搿� 欷勳柎霌媹雼�. 欤检＜霌れ潃 氤戫暕 頉� 氚滌儩頃橂姅 靻岇垬欤检棎 雽�頃� 氤戫暕 歆侅爠 5瓯半灅鞚检潣 膦呹皜 韽夑窢鞚� 旮办鞙茧 順勱笀鞙茧 歆�旮夒皼瓴� 霅╇媹雼�. 霕愴暅 鞚� 氤戫暕鞚� 欤检嫕 氤挫儊瓿� 鞗岆煱韸� 氚� 頃措嫻 頄夓偓臧�毳� 牍勲鞝侅溂搿� 臁办爼頃╇媹雼�.
- NYSE American 靸侅灔 鞖旉贝鞚� 鞙犾頃橂姅 雿� 霃勳泙鞚� 霅╇媹雼�
- 欤检＜霌れ潣 歆�攵� 牍勳湪鞐愲姅 氤�頇旉皜 鞐嗢姷雼堧嫟
- 靻岇垬欤检棎 雽�頃挫劀電� 欤检＜霌れ棎瓴� 鞛愲彊鞙茧 順勱笀鞚� 歆�旮夒惄雼堧嫟
Azitra (NYSE American: AZTR), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e en dermatologie de pr茅cision, a annonc茅 un regroupement d'actions au ratio 1 pour 6,66 prenant effet le 21 ao没t 2025. Les actions ordinaires de la soci茅t茅 continueront d'锚tre n茅goci茅es sous le symbole "AZTR" sur la NYSE American avec un nouveau num茅ro CUSIP 05479L302.
Le regroupement r茅duira le nombre d'actions en circulation d'Azitra de 23,476,354 脿 environ 3,524,978. Les actionnaires recevront de l'argent en lieu et place des actions fractionnaires, calcul茅 sur la base des cours de cl么ture moyens des cinq jours de bourse pr茅c茅dant le regroupement. L'op茅ration ajustera proportionnellement les attributions d'actions et les warrants, y compris leurs prix d'exercice.
- Aidera 脿 maintenir les conditions de cotation sur la NYSE American
- Ne modifie pas le pourcentage de participation des actionnaires dans la soci茅t茅
- Les actionnaires recevront automatiquement de l'argent pour les actions fractionnaires
Azitra (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in klinischer Phase mit Schwerpunkt auf Pr盲zisionsdermatologie, hat eine Aktienzusammenlegung im Verh盲ltnis 1 zu 6,66 angek眉ndigt, die am 21. August 2025 wirksam wird. Die Stammaktien des Unternehmens werden weiterhin unter dem Symbol "AZTR" an der NYSE American gehandelt und erhalten eine neue CUSIP-Nummer 05479L302.
Die Zusammenlegung reduziert die ausstehenden Aktien von Azitra von 23,476,354 auf etwa 3,524,978. Aktion盲re erhalten f眉r Bruchst眉cke Bargeld, berechnet auf Grundlage des durchschnittlichen Schlusskurses der f眉nf Handelstage vor der Zusammenlegung. Die Anpassung wird auch Aktienverg眉tungen und Warrants sowie deren Aus眉bungspreise anteilig anpassen.
- Hilft, die Anforderungen f眉r die Notierung an der NYSE American aufrechtzuerhalten
- 脛ndert nicht den prozentualen Anteil der Aktion盲re am Unternehmen
- Aktion盲re erhalten automatisch Bargeld f眉r Bruchst眉cke
- None.
- Significant reduction in total outstanding shares could impact stock liquidity
- Additional administrative costs for processing fractional shares
- May indicate company's struggle to maintain minimum share price requirements
Insights
Azitra's 1:6.66 reverse split aims to boost share price but signals potential financial concerns without addressing fundamental business issues.
Azitra's announcement of a 1-for-6.66 reverse stock split is a significant financial engineering move that warrants careful investor attention. This maneuver will dramatically reduce the company's outstanding shares from 23,476,354 to approximately 3,524,978, with trading on the split-adjusted basis beginning August 21, 2025.
The unusually precise split ratio of 1:6.66 is noteworthy - most companies opt for cleaner ratios like 1:5 or 1:10. This specific ratio suggests Azitra is precisely targeting a particular post-split share price, likely to meet the NYSE American's continued listing requirements which mandate a minimum share price (typically $1.00).
While reverse splits are technically neutral transactions that don't change a company's underlying value, they historically send concerning signals to the market. Companies typically implement reverse splits after prolonged share price declines, and research shows that stocks undergoing reverse splits often continue underperforming the market post-split.
The timing is also telling - Azitra obtained shareholder approval back in February but waited six months to implement it. This delay suggests management may have been hoping for organic share price recovery that never materialized, forcing their hand with this financial engineering solution. For a clinical-stage biopharmaceutical company focused on precision dermatology, this split addresses share price symptoms rather than potential underlying issues with clinical progress or cash runway.
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025
At a special meeting of stockholders held on February 20, 2025, the Company's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's common stock through an amendment to its Second Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-7, with such ratio to be determined by the Company's Board of Directors. On August 7, 2025, the Board of Directors of Azitra approved the final split ratio of 1-for-6.66 and the effective date of August 21, 2025.聽
At the effective time of the reverse stock split, every 6.66 shares of the Company's issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-6.66 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares of common stock will be issued in connection with the reverse split. Stockholders of record who otherwise would be entitled to receive fractional shares, will be entitled to receive cash (without interest) in lieu of fractional shares, equal to such fraction multiplied by the average of the closing sales prices of the common stock on the NYSE American聽during regular trading hours for the five consecutive trading days immediately preceding the effective date of the reverse split (with such average closing sales prices being adjusted to give effect to the reverse split).
The reverse stock split will reduce the number of issued shares of the Company's common stock from 23,476,354 shares to approximately 3,524,978 shares. Proportional adjustments will be made to the number of shares of the Company's common stock issuable upon exercise or conversion of the Company's equity awards聽and warrants, as well as the applicable exercise price. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company's transfer agent, VStock Transfer Company, at [email protected].
Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on January 14, 2025, which is available free of charge at the SEC's website, , and on the Company's website at .
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of聽S. epidermidis聽designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adults with Netherton syndrome. ATR-04, Azitra's additional clinical program, utilizes another engineered strain of聽S. epidermidis聽for the treatment of EGFR inhibitor ("EGFRi") associated skin toxicity; a Phase 1/2 clinical trial has been initiated for this program. Azitra has received Fast Track designation from the FDA for this program to treat EGFRi associated rash, which impacts approximately 150,000 people in
Contacts
Norman Staskey
Chief Financial Officer
[email protected]
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
箩苍耻驳别苍迟蔼迟颈产别谤别苍诲.肠辞尘听
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
[email protected]
View original content to download multimedia:
SOURCE Azitra, Inc.
FAQ
When will Azitra's (AZTR) reverse stock split take effect?
What is the ratio of Azitra's (AZTR) reverse stock split?
How many shares will Azitra (AZTR) have after the reverse split?
Do Azitra (AZTR) shareholders need to take any action for the reverse split?
What happens to fractional shares in Azitra's (AZTR) reverse split?
